While the clinical trials industry has always been a slacker in innovation, we'll soon start seeing automation and artificial intelligence significantly impacting the way biopharmaceutical enterprises run clinical trials, says Moe Alsumidaie.
News
Advertisement
Advertisement
Advertisement
Therapies aimed at correcting genes that cause diseases are gaining ground in biopharma, some are even specializing in specific mechanisms of action by targeting and modifying RNA through temporary and ongoing treatment. CEO at ProQR Therapeutics, Daniel de Boer, discusses how they are advancing RNA therapies in retinal disorders.
Advertisement
The latest industry happenings, all in one place.
More than 200 biopharma leaders acknowledge that out-of-pocket costs for individuals must be limited to sustain support for fiscal and patent policies key to advancing innovation.
An award made by the European Research Council allows Antonella Viola and her team at the University of Padova to be able to put funds into proof of concept work on using monoamine oxidase B inhibitors as novel drugs targeting NLRP3 inflammasome.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Decision Inputs in Drug Development—Big Vs. Small Pharma: Is There a Difference?
2
Modernizing Recruitment with Data, HCP Networks, and Last Mile Support
3
Rethinking Site Selection and Oversight Amid Complex Protocols
4
ACT Brief: AI Decision-Making, Sponsor Oversight Trends, and HHS Label Changes
5
.png "BioPharm International")
.png "Pharmaceutical Commerce"){kind=logo}
.png "Turbo Machinery Magazine")
.png){kind=spacer}
